| Term | Definition |
|---|---|
| MAA | Marketing authorization application |
| mAb | Monoclonal antibody |
| MAD | Multiple ascending dose |
| MBL | Metallo-β-lactamase |
| MBO/MBI | Management buy-out, or buy-in |
| MDR | Multidrug-resistant |
| MDRO | Multi-drug-resistant organism |
| MIC | Minimum inhibitory concentration |
| micro-ITT | Microbiologic intent-to-treat |
| MITT | Modified intent-to-treat |
| MMDS | Model-based medical decision support |
| MOA | Mode of action |
| MRL | Maximum residue level |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| MRSP | Methicillin resistant Staphylococcus pseudintermedius |
| MSIS | Norwegian Surveillance System for Communicable Disease |
| MSSA | Methicillin-susceptible Staphylococcus aureus |
| MTF | Multilateral Trading Facility (‘stock exchange’) |
| MTV/HTA | Medicinsk teknologivurdering/Health Technology Assessment |
| MVP | Minimum Viable Product (rapid prototyping) |